Sysmex (OTCMKTS:SSMXY) Shares Gap Up – Should You Buy?

Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped up before the market opened on Friday . The stock had previously closed at $9.43, but opened at $10.01. Sysmex shares last traded at $10.01, with a volume of 511 shares.

Wall Street Analysts Forecast Growth

Separately, Zacks Research downgraded shares of Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Sysmex has an average rating of “Hold”.

Sysmex Stock Up 5.2%

The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $6.28 billion, a P/E ratio of 26.26 and a beta of 1.07. The stock has a 50 day moving average price of $8.93 and a 200 day moving average price of $9.07.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings data on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). Sysmex had a return on equity of 7.23% and a net margin of 7.13%.The firm had revenue of $877.92 million for the quarter, compared to the consensus estimate of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. On average, research analysts anticipate that Sysmex Corporation ADR will post 0.42 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.